Cassava Sciences, Inc. Stock News

A struggling biotech stock is on the move today on news of a trial extension. Indeed, Cassava Sciences (NASDAQ: SAVA ) has announced that it will be extending trials of simufilam — its lead Alzheimer's disease treatment candidate — by up to 36 months.

AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in Alzheimer's d...

Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements.

Cassava Sciences (NASDAQ: SAVA ) stock is up on Monday after the company provided investors with an update for its Phase 3 trial for its Alzheimer's disease treatment. According to a news release from Cassava Sciences, the data from its first Phase 3 clinical trial will come out by December 2024.

New Cassava executive chairman Rick Barry wrote an open letter to stakeholders. Barry acknowledged skepticism but stressed the potential for its Alzheimer's disease candidate simufilam.

A bad month just got much worse for Cassava Sciences (NASDAQ: SAVA ). SAVA stock is plunging today on news that President and CEO Remi Barbier is stepping down, effective immediately.

AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.

The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated.